<?xml version="1.0" encoding="UTF-8"?>
<results title="disease">
 <result pre="which vaccines are not yet available. Some of them are" exact="hepatitis" post="C virus (HCV), dengue virus, respiratory syncytial virus, cytomegalovirus,"/>
 <result pre="clinical outcomes: asymptomatic (most common) or mildly symptomatic illness, uncomplicated" exact="dengue fever," post="or more severe disease including plasma leakage, hemorrhage, and"/>
 <result pre="for premembrane (prM) and envelope (E) proteins of the attenuated" exact="yellow fever" post="virus (YFV) 17D vaccine strain for the prM and"/>
 <result pre="partially-attenuated strains of DENV-2 or DENV-3 (29). However, it provokes" exact="rash" post="in more than 60% of those vaccinated (30). The"/>
 <result pre="responses. Viral vectors usually include adenovirus, vaccinia, fowlpox, and vesicular" exact="stomatitis" post="virus (33, 34). It has been proposed that strategies"/>
 <result pre="models against various diseases such as HIV, malaria, and even" exact="cancer" post="(35). In the specific case of malaria control the"/>
 <result pre="malaria, and even cancer (35). In the specific case of" exact="malaria" post="control the studies conducted by Li and coworkers were"/>
 <result pre="pioneers demonstrating that the immunization of mice with a recombinant" exact="vaccinia virus," post="after priming with an influenza virus expressing the same"/>
 <result pre="mice with a recombinant vaccinia virus, after priming with an" exact="influenza" post="virus expressing the same CS protein of the parasite,"/>
 <result pre="parasite can be induced by a single immunization with a" exact="vaccinia virus" post="presenting the CS protein a second dose with the"/>
 <result pre="Rodríguez and colleagues when evaluated the effectiveness of several recombinant" exact="influenza" post="and vaccinia viruses to induce a malaria-specific immune response"/>
 <result pre="studies indicate that complementary prime-boost immunization strategies that use recombinant" exact="vaccinia virus" post="and bacterial plasmids could be useful for the control"/>
 <result pre="the HCV genotype 1a and later boosted with a modified" exact="vaccinia virus" post="Ankara expressing the proteins NS3/4/5B from genotype 1b. This"/>
 <result pre="However, the intracellular bacteria Mycobacterium bovis (M. bovis), which produces" exact="tuberculosis" post="(TB), is able to resist most antibody-mediated antibacterial effects"/>
 <result pre="Intramuscularly 2 doses Prime: plasmid encodingE protein from DENV-2 Boost:" exact="vaccinia virus" post="expressingE protein from DENV-2 Highest levels of E-specific IgG"/>
 <result pre="DENV-2 Highest levels of E-specific IgG in groups immunized with" exact="vaccinia virus," post="but short duration High production of cytokines by CD4+"/>
 <result pre="expressingE protein from DENV-2 Vaccinia DNA Vaccinia/DNA 2 doses Prime:" exact="vaccinia virus" post="expressingE protein from DENV-2 Boost: plasmid encodingE protein from"/>
 <result pre="encodingE protein from DENV-2 Vaccinia Adenovirus Vaccinia/adenovirus 2 doses Prime:" exact="vaccinia virus" post="expressingE protein from DENV-2 Boost: adenovirus expressingE protein from"/>
 <result pre="Adenovirus/vaccinia 2 doses Prime: adenovirus expressingE protein from DENV-2 Boost:" exact="vaccinia virus" post="expressingE protein from DENV-2 2011 Infective virus Recombinant protein"/>
 <result pre="by replacing the prM and E genes from the 17D" exact="yellow fever" post="vaccine virus by those from DENV-2). BALB/c mice were"/>
 <result pre="candidates: a DNA plasmid, a recombinant adenovirus and a recombinant" exact="vaccinia virus." post="All constructions included the E protein from DENV-2 as"/>
 <result pre="sera of anti-E-specific IgG were observed in mice boosted with" exact="vaccinia virus." post="However, when vaccinia virus was used for priming the"/>
 <result pre="were observed in mice boosted with vaccinia virus. However, when" exact="vaccinia virus" post="was used for priming the levels of anti-E antibodies"/>
 <result pre="in vivo CTL killing activity, the group primed with the" exact="vaccinia virus" post="and boosted with the DNA plasmid showed the highest"/>
 <result pre="immunogenicity of a dengue vaccine candidate based on a pediatric" exact="measles" post="vaccine expressing dengue antigens. The vaccine antigen was obtained"/>
 <result pre="from DENV-1. This recombinant construct (EDIII-ectoM) was expressed in a" exact="measles" post="vector (MV). The recombinant MV-EDIII-ectoM induced in MV-susceptible mice,"/>
 <result pre="a monovalent dengue vaccine from DENV-1 or DENV-2 or the" exact="yellow fever" post="vaccine were boosted with Dengvaxia®. The results showed that"/>
 <result pre="was lower than those measured in the group receiving the" exact="yellow fever" post="vaccine and in the naïve group. These results suggest"/>
 <result pre="J Immunol. (2003) 170:2599–604. 10.4049/jimmunol.170.5.259912594287 36.LiSRodriguezMRodriguezDRodriguezJREstebanMPalesePet al.. Priming with recombinant" exact="influenza" post="virus followed by administration of recombinant vaccinia virus induces"/>
 <result pre="Priming with recombinant influenza virus followed by administration of recombinant" exact="vaccinia virus" post="induces CD8+ T-cell-mediated protective immunity against malaria. Proc Natl"/>
 <result pre="(1993) 90:5214–8. 10.1073/pnas.90.11.52147685119 37.RodriguezMLiSMurataKRodriguezDRodriguezJRBacikIet al.. Influenza and vaccinia viruses expressing" exact="malaria" post="CD8+ T and B cell epitopes. Comparison of their"/>
 <result pre="Immunol. (1994) 153:4636–48. 7525709 38.AleshinSETimofeevAVKhoretonenkoMVZakharovaLGPashvykinaGVStephensonJRet al.. Combined prime-boost vaccination against" exact="tick-borne encephalitis" post="(TBE) using a recombinant vaccinia virus and a bacterial"/>
 <result pre="(1994) 153:4636–48. 7525709 38.AleshinSETimofeevAVKhoretonenkoMVZakharovaLGPashvykinaGVStephensonJRet al.. Combined prime-boost vaccination against tick-borne" exact="encephalitis" post="(TBE) using a recombinant vaccinia virus and a bacterial"/>
 <result pre="Combined prime-boost vaccination against tick-borne encephalitis (TBE) using a recombinant" exact="vaccinia virus" post="and a bacterial plasmid both expressing TBE virus non-structural"/>
 <result pre="prime/boost vaccination strategy enhances the immunogenicity of therapeutic vaccines for" exact="hepatitis" post="C virus. J Infect Dis. (2013) 208:1008–19. 10.1093/infdis/jit26723776192 40.SaeediAGhaemiATabarraeiAMoradiAGorjiASemnaniSet"/>
 <result pre="(2013) 208:1008–19. 10.1093/infdis/jit26723776192 40.SaeediAGhaemiATabarraeiAMoradiAGorjiASemnaniSet al.. Enhanced cell immune responses to" exact="hepatitis" post="C virus core by novel heterologous DNA prime/lambda nanoparticles"/>
 <result pre="(2003) 77:8729–35. 10.1128/JVI.77.16.8729-8735.200312885892 45.RodriguesLCDiwanVKWheelerJG. Protective effect of BCG against tuberculous" exact="meningitis" post="and miliary tuberculosis: a meta-analysis. Int J Epidemiol. (1993)"/>
 <result pre="and PPE protein boost provides potent protection against acute Mycobacterium" exact="tuberculosis" post="infection in mice. Microb Pathog. (2016) 93:1–7. 10.1016/j.micpath.2016.01.00626792673 48.SterneJARodriguesLCGuedesIN."/>
 <result pre="combined BCG and killed Mycobacterium leprae vaccine for prevention of" exact="leprosy" post="and tuberculosis in Malawi. Lancet. (1996) 348:17–24. 10.1016/S0140-6736(96)02166-68691924 50.DalmiaNRamsayAJ."/>
 <result pre="and killed Mycobacterium leprae vaccine for prevention of leprosy and" exact="tuberculosis" post="in Malawi. Lancet. (1996) 348:17–24. 10.1016/S0140-6736(96)02166-68691924 50.DalmiaNRamsayAJ. Prime-boost approaches"/>
 <result pre="in Malawi. Lancet. (1996) 348:17–24. 10.1016/S0140-6736(96)02166-68691924 50.DalmiaNRamsayAJ. Prime-boost approaches to" exact="tuberculosis" post="vaccine development. Exp Rev Vaccines. (2012) 11:1221–33. 10.1586/erv.12.9423176655 51.DunachieSJHillAV."/>
 <result pre="Exp Rev Vaccines. (2012) 11:1221–33. 10.1586/erv.12.9423176655 51.DunachieSJHillAV. Prime-boost strategies for" exact="malaria" post="vaccine development. J Exp Biol. (2003) 206:3771–9. 10.1242/jeb.0064214506212 52.OertliMNobenMEnglerDBSemperRPReuterSMaxeinerJet"/>
 <result pre="(2007) 7:10. 10.1186/1472-6750-7-1017302980 68.ChenLEwingDSubramanianHBlockKRaynerJAltersonKDet al.. A heterologous DNA prime-Venezuelan equine" exact="encephalitis" post="virus replicon particle boost dengue vaccine regimen affords complete"/>
 <result pre="cynomolgus macaques. J Virol. (2007) 81:11634–9. 10.1128/JVI.00996-0717715224 69.BrandlerSLucas-HouraniMMorisAFrenkielMPCombredetCFevrierMet al.. Pediatric" exact="measles" post="vaccine expressing a dengue antigen induces durable serotype-specific neutralizing"/>
 <result pre="ONE. (2013) 8:e58357. 10.1371/journal.pone.005835723472186 84.QiaoMShawDForratRWartel-TramALangJ. Priming effect of dengue and" exact="yellow fever" post="vaccination on the immunogenicity, infectivity, and safety of a"/>
 <result pre="indicates that a single dose of the national institute of" exact="allergy" post="and infectious diseases tetravalent dengue vaccine induces a robust"/>
</results>
